Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
scfDNA + polyethylenimine
- Development stage
- Preclinical
- Lead developer
- Mayo Clinic
- Modality
- DNA Therapeutics → Nucleic Acid Therapeutics, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Intraperitoneal, Intratumoral, Subcutaneous, Topical, Intrathecal, Intravitreal, Intranasal, Intra-arterial
01
Overview
scfDNA + polyethylenimine is an experimental DNA nanocarrier designed to mimic the proinflammatory effects of placental cell-free DNA (cfDNA) observed during pregnancy. It consists of a synthetic mimic of fetal cfDNA (scfDNA) complexed with the cationic polymer polyethylenimine (PEI) to facilitate cytosolic delivery. The drug targets the cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway in monocytes and macrophages. By activating the cGAS-STING-IRF signaling axis, it induces a proinflammatory phenotype in tumor-associated macrophages (TAMs), potentially overcoming the immunosuppressive tumor microenvironment. This pregnancy-inspired approach is being developed as a strategy for cancer immunotherapy, specifically for reprogramming myeloid cells within the tumor.
- Other names
- scfDNA-PEI nanoparticlessynthetic fetal cfDNA-polyethylenimine complex
02
Targets
Cyclic GMP–AMP synthaseSTING (Stimulator of interferon genes protein)
Beyond the preview
Go deeper on scfDNA + polyethylenimine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on scfDNA + polyethylenimine.